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Regulation of renal function by prostaglandin E receptors. Pros-
taglandin E2 is the major cyclooxygenase product of arachidonic
acid metabolism produced along the nephron. This autacoid
interacts with four distinct, G-protein—coupled E-prostanoid
receptors designated EP1—EP4. The intrarenal distribution of
each receptor has been mapped and the consequences of receptor
activation examined. EP3 receptor mRNA is expressed highly in
the medullary thick ascending limb (mTAL) and collecting duct
(CD). EP3 receptor activation inhibits cAMP generation via Gi,
thus inhibiting vasopressin-stimulated water reabsorption in the
CD. EP3 receptor activation also may contribute to PGE2-
mediated inhibition of NaCl absorption in the mTAL. The EP1
receptor is coupled to increased cell [Ca21]. EP1 mRNA expres-
sion is restricted to the CD, and receptor activation inhibits Na1
absorption. PGE2 also increases cAMP generation in the cortical
thick ascending limb and CD; this may be due to EP4 receptor
activation. EP4 mRNA is readily detected in the CD with little
detectable EP2 expression. The EP4 receptor appears to be
expressed both on luminal and basolateral membranes. EP4
receptor activation also may contribute to the regulation of renin
release by the juxtaglomerular apparatus. The consequences of
renal EP-receptor activation for salt and water balance may be
determined by the relative renal expression of each of these
receptors.
The prostaglandins (PGs) are a diverse family of auta-
coids derived from cyclooxygenase (COX) metabolism of
arachidonic acid to PGG/H2, leading to the generation of
five primary bioactive autacoids: PGE2, PGF2a PGD2,
PGI2, and thromboxane A2 [1]. PGs play a critical role in
regulating Na1 excretion, blood pressure (BP), and renal
function. This is perhaps highlighted best by the deleterious
side effects of COX inhibitors [nonsteroidal anti-inflamma-
tory drugs (NSAIDs)], which may induce hypertension [2],
Na1 retention, edema, and more rarely, hemodynamically-
mediated renal failure [3, 4]. It is less widely appreciated
that NSAIDs may also reduce BP, especially in patients
with hyperreninemic renovascular hypertension [5]. In this
patient population, aspirin actually decreases BP [6]. These
complex effects of NSAIDs on BP appear to be the result
of competing hypotensive and hypertensive effects of pro-
stanoids, including PGE2, PGI2, and thromboxane A2 [7].
DUAL EFFECTS OF PROSTAGLANDIN E2 ON SALT
BALANCE AND BLOOD PRESSURE
Prosaglandin E2 is the major prostanoid synthesized
along the nephron [8] and potently regulates the renal
microcirculation [9, 10] and salt and water transport [11],
making inhibition of its synthesis an important candidate
for mediating the renal side effects of NSAIDs. Like COX
inhibitors, PGE2 infusion may be either natriuretic or may
promote Na1 retention and hypertension [12]. Typically,
PGE2 is regarded as antihypertensive, and acute intrarenal
PGE2 infusion results in natriuresis and diuresis [13, 14].
NSAIDs are thought to release the kidney from the tonic
natriuretic effects of endogenous PGE2, resulting in Na
1
retention and hypertension [3, 15]. It is thus surprising that
chronic intrarenal PGE2 infusion increases BP in conscious
dogs [16]. The hypertension associated with chronic intra-
renal PGE2 infusion has been ascribed to direct stimulation
of renal renin secretion [16, 17]. The observation that
aspirin reduces BP and renin levels in renovascular hyper-
tension patients is concordant with an important etiologic
role for PGE2-stimulated renin secretion in renovascular
hypertension [5, 6]. In contrast, hypotensive effects of
PGE2 appear to predominate in patients with salt-sensitive
essential hypertension, in whom NSAIDs exacerbate hyper-
tension [15]. In these patients, NSAID-induced hyperten-
sion may result from the loss of tonic PGE2-dependent
natriuresis and dilation of resistance vessels [12]. This
article examines the evidence that these opposing effects of
PGE2 are mediated by distinct G-protein—coupled recep-
tors (E prostanoid or EP receptors) [18] resulting in altered
renal Na1 excretion.
MULTIPLE PROSTAGLANDIN E2 RECEPTORS
Prostaglandin E2 was originally recognized as a potent
vasodilator in both arterial and venous beds [19–22]. This
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effect is mediated, in part, by direct relaxation of vascular
smooth muscle, now thought to be coupled to increased
cAMP generation [19, 20]. However, PGE2 does not relax
all smooth muscle beds uniformly, and it even constricts
trachea, gastric fundus, and ileum [23]. Importantly, struc-
tural analogs of PGE2 that reproduce the dilator effects of
PGE2 are completely inactive in tissues where PGE2 is a
constrictor. Conversely, analogs that reproduce the con-
strictor effects of PGE2 fail to affect tissues in which PGE2
is a dilator [23]. The differential effects of PGE2 analogs
were important initial evidence for the existence of multi-
ple PGE2 receptors [18].
In a screen of compounds for antagonist activity,
SC19220 was a selective EP antagonist, but only where
PGE2 was a smooth muscle constrictor [23]. These recep-
tors were originally designated EP1, whereas SC19220-
insensitive dilator effects were ascribed to a distinct recep-
tor, designated EP2. The differential sensitivity of tissues to
several structural PGE analogs has led to the identification
of at least four distinct EP receptors: the dilator receptors
EP2 and EP4 and the constrictor receptors EP1 and EP3.
The existence and molecular characterization of the four
receptors have now been confirmed and characterized
further by molecular cloning (Table 1). Although the EP1
receptor was originally classified by its smooth muscle
constrictor effects and the EP4 receptor by its vasodilator
action, the consequences for Na1 balance and BP of
activating renal EP1 and EP4 receptors may be quite
different from the effects on smooth muscle.
E-PROSTANOID RECEPTOR PHARMACOLOGY
The EP receptors are members of the G-protein—
coupled family of receptors, possessing seven hydrophobic,
membrane-spanning amino acid sequences [24]. EP1 recep-
tors signal mainly via phosphatidylinositol biphosphate
hydrolysis and couple to increased cell Ca21 [25–27]. EP1
receptors are distinguished by the availability of selective
antagonists (such as, AH6809 and SC19220), which block
activation (Table 1). No absolutely selective EP1 agonists
have been reported. In contrast, vasodilator EP2 and EP4
receptors signal through increased cAMP [28–30]. EP2
receptors are activated selectively by butaprost, whereas
high AH23848 concentrations block EP4, but not EP2,
receptors [21, 30]. (The literature is somewhat confusing
because prior to 1995, the cloned EP4 receptor was cate-
gorized incorrectly as EP2 [31].) EP3 receptors inhibit
cAMP generation via a pertussis toxin-sensitive, Gi-coupled
mechanism and constrict smooth muscle [32, 33]. MB28767
and sulprostone are selective and potent EP3 agonists but
have variable activity at the EP4 and EP1 receptors, respec-
tively. The EP3 receptor is unique among the EP receptors
in that numerous alternatively spliced variants exist, differ-
ing only in their carboxy-terminal tail [33–35]. Importantly,
these EP3 splice variants couple differentially to alternate
signaling mechanisms, including phosphatidylinositol bi-
phosphate hydrolysis and increased cAMP (albeit at ligand
concentrations typically 100- to 1000-fold greater than
those required to inhibit cAMP generation via Gi) [35, 36].
Whether these signaling differences in EP3 splice variants
are physiologically relevant remains to be determined. The
study of EP receptor physiology has been hampered signif-
icantly by the lack of receptor-selective agonists and antag-
onists. In this regard, the availability of mice with targeted
disruption of specific EP receptor genes should prove an
invaluable resource for evaluating the function of specific
EP receptors [37, 38].
PROSTAGLANDIN E2 ACTION IN THE THICK
ASCENDING LIMB
The multiplicity of EP receptors may underlie many of
the complexities of PGE2 action on salt and water transport
along the nephron [39]. In the intact animal, intrarenal
Table 1. E-prostanoid receptor pharmacology
Subtype IC50/Kd Agonists
a Antagonists Functional assay Signaling Tissue mRNA expression
EP1b 1-20 nM 17-phenyl-trinor-
PGE2, iloprost
SC19220
SC51089
Contracts: guinea-pig ileum,
gastric fundus
IP3/DAG/PKC Collecting duct
Muscularis mucosae,
sulprostone AH6809 trachea hypothalamus
EP2 20 nM Butaprost
AH13205
— Relaxes: rabbit ear artery,
guinea-pig ileum, trachea
Increased cAMP Uterus
Arterial
EP3b 0.3-2 nM MB28767
sulprostone
misoprostol
1l-deoxy-PGE1
— Contracts: chick ileum,
inhibits gastric acid
secretion
Decreased cAMP/Gi
rho, and other
pathways
Stomach epithelium,
kidney, collecting duct,
thick limb
EP4 2-11 nM 1l-deoxy-PGE1
MB28767(?)
misoprostol
AH23848 Dilates: saphenous vein,
jugular vein
ductus arteriosus
Increased cAMP Ureter/bladder, kidney,
thymus
intestinal epithelia
Abbreviations are: EP, E-prostanoid; IP3, inositol triphospate: PKC, protein kinase C.
a These agonists are only relatively selective and may activate other EP receptors at higher concentrations
b splice variants exists that may have alternate signaling and functional effects
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PGE2 infusion elicits natriuresis and diuresis without sig-
nificant changes in glomerular filtration or renal blood flow,
consistent with its inhibition of salt absorption along the
nephron [13, 14, 16]. This effect may reflect PGE2’s well-
demonstrated capacity to inhibit salt and water absorption
in the thick ascending limb (TAL) and collecting duct (CD)
directly [40–43]. Stokes first demonstrated that PGE2
directly inhibits Cl2 absorption in the rabbit medullary
TAL (mTAL) from either luminal or basolateral surfaces
[42]. PGE2 was shown also to inhibit vasopressin- or
calcitonin-stimulated cAMP generation in TAL [44, 45].
Because cAMP stimulates TAL transport, inhibition of
cAMP generation by PGE2 may explain PGE2’s inhibitory
effects on TAL transport [46]. With EP3-selective ribo-
probes, it has been shown that mRNA for the Gi-coupled
EP3 receptor is expressed in TAL, suggesting that it may
mediate the observed inhibition of cAMP generation in this
segment [47–49]. Consistent with this, Good has demon-
strated modulation of ion transport by PGE2 in the rat TAL
by a pertussis toxin-sensitive mechanism; however, these
effects possibly also involve protein kinase C activation [43,
50]. Taken together, these data support a role for the EP3
receptor in regulating TAL transport. This interpretation is
complicated by the observation that, given alone, PGE2,
but not the EP3 agonist sulprostone, also potently stimu-
lates cortical TAL (cTAL, Tamm-Horsfall positive) cAMP
generation [45, 51]. This suggests that a cAMP-coupled EP
receptor (EP2 or EP4) might predominate in Tamm-Hors-
fall—positive cortical nephron segments, including cTAL
or distal convoluted tubule [52]. If so, PGE2-stimulated
cAMP generation also could enhance NaCl absorption in
these segments. A functional correlate for this possibility
has yet not been established [42].
MULTIPLE E-PROSTANOID RECEPTORS AND
PROSTAGLANDIN E2 EFFECTS ON TRANSPORT IN
THE COLLECTING DUCT
In contrast to the mTAL and cTAL, PGE2’s capacity to
either increase or decrease cortical CD (CCD) water
reabsorption and cAMP generation is well established.
Added to vasopressin-stimulated CDs, PGE2 potently in-
hibits water absorption [40], consistent with the classic
diuretic effects of PGE2 infusion [13, 53]. However, in the
absence of vasopressin, basolateral PGE2 actually increases
osmotic water absorption [40, 53, 54]. PGE2 also simulta-
neously inhibits CCD Na1 absorption. Thus, at least three
distinct transport effects of basolateral PGE2 have been
described: stimulation of basal water absorption, inhibition
of vasopressin-stimulated water absorption, and inhibition
of Na11 absorption. Importantly, luminal PGE2 also in-
creases basal water absorption and transiently stimulates an
amiloride-sensitive current, suggesting that urinary PGE2
may also affect salt and water transport [54] (Fig. 1). As in
smooth muscle, the distinct effects of PGE2 in the CCD
appear to be mediated by separate, coexpressed EP recep-
tors [47, 55].
The diverse effects of PGE2 in the CD appear to be
mediated by distinct signaling pathways [39–41]. PGE2
inhibits vasopressin-stimulated osmotic water absorption in
the CCD via a pertussis toxin-sensitive process coupled to
inhibition of cAMP generation, presumably via Gi [41, 56,
57]. These functional data fit well with molecular studies
localizing the EP3 receptor to the CD and TAL (as
described earlier here). In situ hybridization with EP3-
selective riboprobes shows high levels of EP3 mRNA
expression in human, rabbit, and mouse CD [47, 48, 55], a
Fig. 1. Cellular localization, signaling, and
functional consequences of E-prostanoid (EP)
receptor activation in the collecting duct.
Abbreviations are: ATP, adenosine
triphosphate; IP3, inositol triphosphate; PGE,
prostaglandin E; PIP2, phosphatidylinositol
biphosphate; PKC, protein kinase C; PLC,
phospholipase C.
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finding confirmed by reverse transcription-polymerase
chain reaction on microdissected rat and mouse CD [49,
58]. Importantly, PGE2-mediated inhibition of Na
1 absorp-
tion is entirely unaffected by pertussis toxin [41] but is
rather Ca21/protein kinase C dependent [41, 59, 60].
As opposed to EP3-mediated inhibition of water absorp-
tion, evidence suggests that an EP1 receptor initiates the
Ca21/protein kinase C-coupled inhibition of CCD Na1
absorption [40, 41, 61]. The cloned mouse and human EP1
receptors have been shown to signal via stimulation of
inositol triphosphate generation and increased intracellular
[Ca21] [25, 27]. Interestingly, the tissue distribution of EP1
receptor mRNA shows it is predominantly expressed in the
kidney [25, 62, 63]. PGE2 increases intracellular Ca
21 in the
CD, and maneuvers that prevent the Ca21 increase com-
pletely block PGE2-mediated inhibition of Na
1 absorption
[41]. Recently, two different EP1 receptor antagonists,
AH6809 and SC19220, have been shown to block both the
PGE2-stimulated Ca
21 increase and PGE2’s capacity to
inhibit Na1 absorption [61]. Finally, in situ hybridization
shows that renal EP1 receptor expression is localized
exclusively in the CD [48, 55, 64]. Together, these results
strongly suggest that the EP1 receptor stimulates Ca
21-
coupled inhibition of CD Na1 transport.
The contribution of EP1 receptor activation to PGE2-
mediated natriuresis remains uncertain. Although in vitro
conditions allow the effective use of EP1 receptor antago-
nists, the efficacy of the EP1 antagonists in vivo has been
severely limited by their poor solubility, binding to serum
albumin, and their relatively low potency [23, 65]. Never-
theless, continued work toward the development of clini-
cally active EP1 receptor antagonists has been driven by
evidence that the EP1 receptor is important in PG-medi-
ated pain and fever [66, 67]. It will be critical to determine
whether EP1 receptor antagonists have analgesic and anti-
pyretic activity. As with NSAIDs, renal side effects of EP1
antagonists may occur. If so, EP1 receptor antagonists
might reduce renal Na1 excretion and thereby result in
hypertension.
Basolateral PGE2 increases water absorption in the CD,
apparently by stimulating basal cAMP production [40, 54,
60]. EP2 and EP4 receptors signal via Gs-stimulated cAMP
generation. EP2 receptor mRNA is not detected in human
kidney by in situ hybridization [55], and although EP4
receptor mRNA is most notably expressed in the glomer-
ulus, it is also detected in the epithelial cells of ureter and
bladder, with less intense expression in the CD [29, 55]. The
EP-selective analog (EP2/3/4) 11-deoxy-PGE1 stimulates
cAMP generation in the CCD, whereas the EP1/3-active
analog sulprostone and the EP2-selective analog butaprost
are inactive [56, 68]. These data suggest that an EP4
receptor mediates cAMP-stimulated water absorption in
the CD. Interestingly, a similar EP receptor also appears to
be present in the CD lumen [54]. Activation of the luminal
receptor occurs with PGE2 and 11-deoxy-PGE1, but not
sulprostone, and increases basal water absorption and
transiently hyperpolarizes the lumen negative voltage.
Thus, urinary PGE2 may modulate renal salt and water
transport [54, 69].
The possibility that PGE2 enhances renal Na
1 absorp-
tion via an EP4 receptor is intriguing with respect to PGE2’s
contribution to certain forms of hypertension. Although
NSAIDs typically reduce Na1 excretion in anesthetized
animals, one intriguing study has shown a marked increase
in urinary Na1 excretion, without any change in urine
volume or renal hemodynamics, when meclofenamate or
carprofen is administered to conscious dogs undergoing a
water diuresis [70]. This suggests that under these particu-
lar circumstances, endogenous PGs enhance Na1 absorp-
tion along the nephron. The capacity of PGE2 to increase
Na1 absorption in toad bladder has been known for more
than 25 years [71], so a similar capacity in renal epithelia is
not surprising. It is of note in this regard that PGE2 is
thought to enter the urine in the loop of Henle and would
thus have access to a cAMP-stimulating luminal EP recep-
tor in distal nephron segments [72, 73]. The possibility that
enhanced distal Na1 absorption contributes to PG-depen-
dent, hyperreninemic renovascular hypertension [6] re-
mains unexplored.
E-PROSTANOID RECEPTORS AND RENIN RELEASE
Chronic intrarenal PGE2 infusion produces hypertension
that is accounted for primarily by increased renin release
without an altered Na1 balance [16]. Because increased
cAMP may mediate PGE2-induced renin release, an EP4
(or EP2) receptor could also mediate increased renin
release [17]. PGE2 and PGI2 can stimulate cAMP genera-
tion independently in isolated preglomerular renal arte-
rioles (Fig. 2). Furthermore, cAMP directly stimulates
renin release from cultured mouse juxtaglomerular appa-
ratus (JGA) cells [17, 74]. Although localization of EP2 or
EP4 receptors in the JGA has not been demonstrated, EP4
receptor mRNA is expressed in the glomerulus [29, 48, 55].
It is therefore conceivable that renal EP4 receptor activa-
tion could increase BP both by enhancing renin release and
increasing distal Na1 absorption. The latter might be
mediated via effects in the cTAL, the CD, or both. This
possibility is tempered by the fact that the precise mecha-
nism by which PGs contribute to renin release remains
elusive, and in situ localization of EP receptors to the JGA
has not been demonstrated. Rather, one report demon-
strates EP3 receptor mRNA is localized over the macula
densa, suggesting this cAMP-inhibiting receptor may also
contribute to the control of renin release [48].
In summary, EP1, EP3, and EP4 receptors appear to
coexist in individual nephron segments, including the TAL
and CD (Fig. 2). EP1 and EP3 receptors may contribute to
the natriuretic and diuretic action of PGE2. In contrast,
intrarenal EP4 receptors may activate cAMP-stimulated
salt and water absorption along the nephron. Finally, EP
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receptors also appear to play an important role in regulat-
ing renin release. These receptors may provide novel
targets for modulating renal salt and water excretion as well
as systemic BP. It seems likely that the present limited
clinical utility of PG analogs will be transformed by the
availability of truly receptor-selective antagonists.
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